Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical application of anti-M$\ddot{u}$llerian hormone as a predictor of controlled ovarian hyperstimulation outcome

  • Lee, Jae Eun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Lee, Jung Ryeol (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Jee, Byung Chul (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Suh, Chang Suk (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Kim, Ki Chul (Hamchoon Women's Clinics) ;
  • Lee, Won Don (Maria Infertility Hospital) ;
  • Kim, Seok Hyun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
  • Received : 2012.08.15
  • Accepted : 2012.11.08
  • Published : 2012.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: In 2009 anti-M$\ddot{u}$llerian hormone (AMH) assay was approved for clinical use in Korea. This study was performed to determine the reference values of AMH for predicting ovarian response to controlled ovarian hyperstimulation (COH) using the clinical assay data. Methods: One hundred sixty-two women who underwent COH cycles were included in this study. We collected data on age, basal AMH and FSH levels, total dose of gonadotropins, stimulation duration, and numbers of oocytes retrieved and fertilized. Blood samples were obtained on cycle day 3 before gonadotropin administration started. Serum AMH levels were measured at a centralized clinical laboratory center. The correlation between the AMH level and COH outcomes and cut-off values for poor and high response after COH was analyzed. Results: Concentration of AMH was significantly correlated with the number of oocytes retrieved (OPU; r=0.700, p<0.001). The mean${\pm}$SE serum AMH levels for poor ($OPU{\leq}3$), normal ($4{\leq}OPU{\leq}19$), and high ($OPU{\geq}20$) response were $0.94{\pm}0.15$ ng/mL, $2.79{\pm}0.21$ ng/mL, and $6.94{\pm}0.90$ ng/mL, respectively. The cut-off level, sensitivity and specificity for poor and high response were 1.08 ng/mL, 85.8%, and 78.6%; and 3.57 ng/mL, 94.4%, and 83.3%, respectively. Conclusion: Our data present clinical reference values of the serum AMH level for ovarian response in Korean women. The serum AMH level could be a clinically useful predictor of ovarian response to COH.

Keywords

References

  1. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468-71. https://doi.org/10.1016/S0015-0282(01)03201-0
  2. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen- Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 2004;82:1323-9. https://doi.org/10.1016/j.fertnstert.2004.03.061
  3. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77:357-62. https://doi.org/10.1016/S0015-0282(01)02993-4
  4. Shin SY, Lee JR, Noh GW, Kim HJ, Kang WJ, Kim SH, et al. Analysis of serum levels of anti-Mullerian hormone, inhibin B, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and follicle-stimulating hormone with respect to age and menopausal status. J Korean Med Sci 2008;23:104-10. https://doi.org/10.3346/jkms.2008.23.1.104
  5. van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17:3065-71. https://doi.org/10.1093/humrep/17.12.3065
  6. Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS, et al. Anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction. Hum Reprod 2010;25:2597-604. https://doi.org/10.1093/humrep/deq204
  7. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril 2007;87:223-6. https://doi.org/10.1016/j.fertnstert.2006.06.019
  8. McIlveen M, Skull JD, Ledger WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 2007;22:778-85. https://doi.org/10.1093/humrep/del435
  9. Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod 2008;23:1359-65. https://doi.org/10.1093/humrep/den108
  10. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 2010;93:855-64. https://doi.org/10.1016/j.fertnstert.2008.10.042
  11. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al. Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008;23:160-7.
  12. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24: 867-75.
  13. Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et al. Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarianstimulation for in vitro fertilization. Fertil Steril 2009;92:1586-93. https://doi.org/10.1016/j.fertnstert.2008.08.127
  14. Choi MH, Yoo JH, Kim HO, Cha SH, Park CW, Yang KM, et al. Serum anti-Mullerian hormone levels as a predictor of the ovarian response and IVF outcomes. Clin Exp Reprod Med 2011;38:153-8. https://doi.org/10.5653/cerm.2011.38.3.153
  15. van Rooij IA, Broekmans FJ, Hunault CC, Scheffer GJ, Eijkemans MJ, de Jong FH, et al. Use of ovarian reserve tests for the prediction of ongoing pregnancy in couples with unexplained or mild male infertility. Reprod Biomed Online 2006;12:182-90. https://doi.org/10.1016/S1472-6483(10)60859-0
  16. Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD, te Velde ER. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002;77:328-36. https://doi.org/10.1016/S0015-0282(01)02983-1
  17. Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 2005;20: 3178-83. https://doi.org/10.1093/humrep/dei203
  18. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007;22:766-71. https://doi.org/10.1093/humrep/del421
  19. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 2006;91:4057-63. https://doi.org/10.1210/jc.2006-0331
  20. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006; 85:592-6. https://doi.org/10.1016/j.fertnstert.2005.09.019
  21. Freour T, Mirallie S, Bach-Ngohou K, Denis M, Barriere P, Masson D. Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 2007;375: 162-4. https://doi.org/10.1016/j.cca.2006.06.013
  22. Bersinger NA, Wunder D, Birkhäuser MH, Guibourdenche J. Measurement of anti-mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid. Clin Chim Acta 2007;384:174-5. https://doi.org/10.1016/j.cca.2007.05.011
  23. Streuli I, Fraisse T, Chapron C, Bijaoui G, Bischof P, de Ziegler D. Clinical uses of anti-Mullerian hormone assays: pitfalls and promises. Fertil Steril 2009;91:226-30. https://doi.org/10.1016/j.fertnstert.2007.10.067
  24. Lee JR, Kim SH, Jee BC, Suh CS, Kim KC, Moon SY. Antimullerian hormone as a predictor of controlled ovarian hyperstimulation outcome: comparison of two commercial immunoassay kits. Fertil Steril 2011;95:2602-4. https://doi.org/10.1016/j.fertnstert.2011.01.126
  25. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113-30. https://doi.org/10.1093/humupd/dmp036
  26. Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-Mullerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737-43. https://doi.org/10.1016/j.fertnstert.2007.07.1293
  27. Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? BJOG 2004;111:1248-53. https://doi.org/10.1111/j.1471-0528.2004.00452.x
  28. Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Anti-mullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol 2005;45:20-4. https://doi.org/10.1111/j.1479-828X.2005.00332.x
  29. Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril 2005;84:555-69. https://doi.org/10.1016/j.fertnstert.2005.02.053
  30. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;(3):CD001750.

Cited by

  1. Association study of anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms with idiopathic primary ovarian insufficiency vol.28, pp.12, 2012, https://doi.org/10.1093/humrep/det384
  2. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice vol.20, pp.1, 2012, https://doi.org/10.1093/humupd/dmt037
  3. Dynamics of anti-Müllerian hormone during controlled ovarian stimulation vol.30, pp.2, 2012, https://doi.org/10.3109/09513590.2013.860124
  4. Clinical application of serum anti-Müllerian hormone in women vol.46, pp.2, 2012, https://doi.org/10.5653/cerm.2019.46.2.50